2024
Underuse of Lifesaving Medications for Opioid Use Disorder in US Jails
Springer S. Underuse of Lifesaving Medications for Opioid Use Disorder in US Jails. JAMA Network Open 2024, 7: e2434649. PMID: 39316405, DOI: 10.1001/jamanetworkopen.2024.34649.Peer-Reviewed Original Research
2020
The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons A Systematic Review
Seval N, Wurcel A, Gunderson CG, Grimshaw A, Springer SA. The Impact of Medications for Opioid Use Disorder on Hepatitis C Incidence Among Incarcerated Persons A Systematic Review. Infectious Disease Clinics Of North America 2020, 34: 559-584. PMID: 32782102, PMCID: PMC7437982, DOI: 10.1016/j.idc.2020.06.011.Peer-Reviewed Original Research
2018
Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community
Springer SA, Di Paola A, Barbour R, Azar MM, Altice FL. Extended-release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living with HIV and Alcohol use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 79: 92-100. PMID: 29781884, PMCID: PMC6092223, DOI: 10.1097/qai.0000000000001759.Peer-Reviewed Original ResearchConceptsAlcohol use disorderViral suppressionExtended-release naltrexoneXR-NTXPlacebo groupPlacebo-controlled trialMonthly injectionsSecondary outcomesTreat analysisIncarcerated individualsEligible participantsWhite raceUse disordersAlcohol consumptionHIVMonthsNaltrexoneBaselineDisordersInjectionIncarcerated peopleParticipantsPlaceboGroupSuppressionRisk behaviors and HIV care continuum outcomes among criminal justice-involved HIV-infected transgender women and cisgender men: Data from the Seek, Test, Treat, and Retain Harmonization Initiative
Beckwith CG, Kuo I, Fredericksen RJ, Brinkley-Rubinstein L, Cunningham WE, Springer SA, Loeliger KB, Franks J, Christopoulos K, Lorvick J, Kahana SY, Young R, Seal DW, Zawitz C, Delaney JA, Crane HM, Biggs ML. Risk behaviors and HIV care continuum outcomes among criminal justice-involved HIV-infected transgender women and cisgender men: Data from the Seek, Test, Treat, and Retain Harmonization Initiative. PLOS ONE 2018, 13: e0197730. PMID: 29787580, PMCID: PMC5963777, DOI: 10.1371/journal.pone.0197730.Peer-Reviewed Original ResearchConceptsHIV care continuum outcomesCare continuum outcomesContinuum outcomesTransgender womenCisgender menViral suppressionHIV riskCondomless sexRisk behaviorsSexual partnersExchange sexMean percent adherenceCrack/cocaineMultiple sexual partnersRisk reduction interventionsHigh rateHIV continuumHIV infectionPercent adherenceCare outcomesHIVReduction interventionsCocaine useDrug abuseCJ systemExtended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community
Springer SA, Di Paola A, Azar M, Barbour R, Biondi BE, Desabrais M, Lincoln T, Skiest DJ, Altice FL. Extended-Release Naltrexone Improves Viral Suppression Among Incarcerated Persons Living With HIV With Opioid Use Disorders Transitioning to the Community. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2018, 78: 43-53. PMID: 29373393, PMCID: PMC5889326, DOI: 10.1097/qai.0000000000001634.Peer-Reviewed Original ResearchMeSH KeywordsAdultCriminal LawDelayed-Action PreparationsDouble-Blind MethodFemaleFollow-Up StudiesHIV InfectionsHIV-1HumansInjections, IntramuscularMaleMiddle AgedMultivariate AnalysisNaltrexoneNarcotic AntagonistsOpioid-Related DisordersPrisonersProspective StudiesResearch DesignRNA, ViralTime FactorsTreatment OutcomeViral LoadConceptsOpioid use disorderViral suppressionXR-NTXPlacebo groupPrimary outcomeUse disordersXR-NTX groupPlacebo-controlled trialExtended-release naltrexoneStatistical significant differenceRelease naltrexoneMonthly injectionsEligible participantsTreatment groupsJail detaineesHIVMonthsBaselinePlaceboSignificant differencesNaltrexoneJail inmatesDisordersVS levelsOutcomes
2017
Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community
Springer SA, Di Paola A, Azar MM, Barbour R, Krishnan A, Altice FL. Extended-release naltrexone reduces alcohol consumption among released prisoners with HIV disease as they transition to the community. Drug And Alcohol Dependence 2017, 174: 158-170. PMID: 28334661, PMCID: PMC5407009, DOI: 10.1016/j.drugalcdep.2017.01.026.Peer-Reviewed Original ResearchConceptsHeavy drinking daysAlcohol use disorderFirst heavy drinking dayExtended-release naltrexoneXR-NTXDrinking daysPlacebo groupAlcohol consumptionDrinks/drinking dayPlacebo-controlled trialSerious adverse eventsDrinks/daySignificant differencesMonthly injectionsAdverse eventsHIV diseaseHIV outcomesTreatment armsAlcohol scoresMAIN OUTCOMEAlcohol consumption scoresUse disordersImprovement scoresDrinking outcomesNaltrexone
2015
HIV-infected men who have sex with men, before and after release from jail: the impact of age and race, results from a multi-site study
Vagenas P, Zelenev A, Altice FL, Di Paola A, Jordan AO, Teixeira PA, Frew PM, Spaulding AC, Springer SA. HIV-infected men who have sex with men, before and after release from jail: the impact of age and race, results from a multi-site study. AIDS Care 2015, 28: 22-31. PMID: 26275122, PMCID: PMC4713253, DOI: 10.1080/09540121.2015.1062464.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAge FactorsAnti-HIV AgentsBlack or African AmericanBlack PeopleContinuity of Patient CareHealth Services AccessibilityHealthcare DisparitiesHIV InfectionsHomosexuality, MaleHumansInsurance, HealthKaplan-Meier EstimateMalePrisonersPrisonsRacial GroupsTreatment OutcomeYoung AdultConceptsBlack MSMHIV healthcare providersHIV treatment outcomesDisease management interventionsHIV/AIDS epidemicYoung Black MSMImpact of ageNon-black MSMHigher infection rateYoung HIVTreatment outcomesLarge cohortWorst HIVHIVHealth outcomesJail detaineesMale subgroupHealthcare providersInfection rateMulti-site studyMSMAIDS epidemicMenBlack menInterventionPrevalence and Predictors of Mental/Emotional Distress Among HIV+ Jail Detainees at Enrollment in an Observational Study
Lincoln T, Simon-Levine D, Smith J, Donenberg GR, Springer SA, Zaller N, Altice FL, Moore K, Jordan AO, Draine J, Desabrais M. Prevalence and Predictors of Mental/Emotional Distress Among HIV+ Jail Detainees at Enrollment in an Observational Study. Journal Of Correctional Health Care 2015, 21: 125-139. PMID: 25788608, PMCID: PMC4433291, DOI: 10.1177/1078345815574566.Peer-Reviewed Original ResearchConceptsEmotional distressJail detaineesSeverity Index scoreAddiction Severity Index (ASI) scoresPoor physical healthMental health assessmentHIV/AIDSEmotional distress scoresObservational studyIndex scoreDistress scoresHealth servicesHealth RankingsSubstance abusePhysical healthJail systemHealth assessmentBisexual orientationSpecific correlatesDistressFamily supportPrevalenceScoresHigh levelsPLWHA
2014
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community
Di Paola A, Lincoln T, Skiest DJ, Desabrais M, Altice FL, Springer SA. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for HIV-infected, opioid dependent prisoners and jail detainees who are transitioning to the community. Contemporary Clinical Trials 2014, 39: 256-268. PMID: 25240704, PMCID: PMC4283549, DOI: 10.1016/j.cct.2014.09.002.Peer-Reviewed Original ResearchConceptsOpioid agonist treatmentPlacebo-controlled trialXR-NTXAgonist treatmentOpioid dependenceTreatment outcomesPoor HIV treatment outcomesOpioid treatment outcomesOpioid-dependent prisonersExtended-release naltrexoneHIV treatment outcomesHIV transmission riskEvidence-based treatmentsCriminal justice settingsEarly acceptabilityStudy medicationFirst injectionStudy acceptabilityHIVTotal referralsJail detaineesCommunity settingsTransmission riskDrug relapseHigh internal validityOptimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate
Meyer JP, Cepeda J, Wu J, Trestman RL, Altice FL, Springer SA. Optimization of Human Immunodeficiency Virus Treatment During Incarceration: Viral Suppression at the Prison Gate. JAMA Internal Medicine 2014, 174: 721-729. PMID: 24687044, PMCID: PMC4074594, DOI: 10.1001/jamainternmed.2014.601.Peer-Reviewed Original ResearchConceptsHIV-1 RNA levelsCD4 lymphocyte countViral suppressionHIV viral suppressionLymphocyte countObserved therapyRNA levelsBaseline HIV-1 RNA levelsMean HIV-1 RNA levelHuman immunodeficiency virus (HIV) treatmentHuman immunodeficiency virus managementHIV treatment outcomesRetrospective cohort studyAntiretroviral therapy regimensHIV-1 RNAPsychiatric disorder severityLogistic regression modelsCommunity-based resourcesDuration of incarcerationRace/ethnicityART regimenContinuous ARTPrescribed pharmacotherapyAntiretroviral therapyART regimensAn evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone
Vagenas P, Di Paola A, Herme M, Lincoln T, Skiest DJ, Altice FL, Springer SA. An evaluation of hepatic enzyme elevations among HIV-infected released prisoners enrolled in two randomized placebo-controlled trials of extended release naltrexone. Journal Of Substance Use And Addiction Treatment 2014, 47: 35-40. PMID: 24674234, PMCID: PMC4042403, DOI: 10.1016/j.jsat.2014.02.008.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialXR-NTXGamma-glutamyl transferaseAlanine aminotransferaseMental illnessAspartate aminotransferaseRandomized placebo-controlled trialMonthly injectable formulationXR-NTX armExtended-release naltrexoneHepatic enzyme elevationHepatic enzyme levelsRelease naltrexoneAntiretroviral therapyHCV infectionBaseline characteristicsHepatic transaminasesEnzyme elevationPsychiatric medicationsHepatotoxicity concernsGlutamyl transferaseAlcohol dependenceOpioidsHIVNaltrexone
2013
Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community
Springer SA, Altice FL, Herme M, Di Paola A. Design and methods of a double blind randomized placebo-controlled trial of extended-release naltrexone for alcohol dependent and hazardous drinking prisoners with HIV who are transitioning to the community. Contemporary Clinical Trials 2013, 37: 209-218. PMID: 24384538, PMCID: PMC3992862, DOI: 10.1016/j.cct.2013.12.006.Peer-Reviewed Original ResearchConceptsPlacebo-controlled trialHIV treatment outcomesTreatment outcomesCriminal justice system (CJS) populationsPoor antiretroviral therapy (ART) adherenceAlcohol useExtended-release naltrexoneAntiretroviral therapy adherenceMedication-assisted therapyPrevention of relapseAlcohol use disorderSexual risk-taking behaviorsAlcohol-dependent personsXR-NTXHigh morbidityTherapy adherenceAlcohol relapseHigh prevalenceStudy participationEligibility criteriaUse disordersHIVRelapseHazardous drinkingNaltrexonePartner violence and health among HIV-infected jail detainees
Meyer JP, Wickersham JA, Fu JJ, Brown SE, Sullivan TP, Springer SA, Altice FL. Partner violence and health among HIV-infected jail detainees. International Journal Of Prisoner Health 2013, 9: 124-141. PMID: 24376468, PMCID: PMC3873166, DOI: 10.1108/ijph-03-2013-0011.Peer-Reviewed Original ResearchConceptsIntimate partner violenceSubstance use disordersHIV treatment outcomesHealthcare utilizationPartner violenceTreatment outcomesJail detaineesIPV exposureEffects of IPVHIV secondary preventionPost-release interventionsUntreated mental disordersDepth qualitative interviewsLifetime IPV exposureForms of childhoodHigher alcohol use severityCriminal justice populationsAlcohol use severityViolence reductionCJ populationsTime of incarcerationHIV diagnosisSecondary preventionAdulthood abuseQualitative interviewsContribution of Substance Use Disorders on HIV Treatment Outcomes and Antiretroviral Medication Adherence Among HIV-Infected Persons Entering Jail
Chitsaz E, Meyer JP, Krishnan A, Springer SA, Marcus R, Zaller N, Jordan AO, Lincoln T, Flanigan TP, Porterfield J, Altice FL. Contribution of Substance Use Disorders on HIV Treatment Outcomes and Antiretroviral Medication Adherence Among HIV-Infected Persons Entering Jail. AIDS And Behavior 2013, 17: 118-127. PMID: 23673792, PMCID: PMC3818019, DOI: 10.1007/s10461-013-0506-0.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAlcohol DrinkingAnti-Retroviral AgentsComorbidityCross-Sectional StudiesFemaleHIV InfectionsHumansLogistic ModelsMaleMedication AdherenceMiddle AgedPrisonersPrisonsSocioeconomic FactorsSubstance Abuse, IntravenousSubstance-Related DisordersTreatment OutcomeUnited StatesYoung AdultConceptsAntiretroviral medication adherenceSubstance use disordersMedication adherenceUse disordersEvidence-based drug treatmentHIV care providersHIV treatment engagementHIV treatment outcomesMedication-assisted therapyMulti-faceted interventionPaucity of evidenceDrug use severityAntiretroviral therapyPoor outcomePsychiatric comorbidityHIV treatmentTreatment outcomesDrug treatmentCare providersJail detaineesTreatment engagementUS sitesSubstance useVulnerable populationsUse severity
2012
Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners
Springer SA, Qiu J, Saber-Tehrani AS, Altice FL. Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners. PLOS ONE 2012, 7: e38335. PMID: 22719814, PMCID: PMC3365007, DOI: 10.1371/journal.pone.0038335.Peer-Reviewed Original ResearchConceptsMaximum viral suppressionOpioid dependenceViral suppressionGlobal health qualityMaximal viral suppressionHIV treatment outcomesBuprenorphine/naloxoneCopies/mLChronic relapsing diseaseDSM-IV criteriaAntiretroviral therapyOpioid useProspective trialProspective studyRelapsing diseaseOpioid dependentsTreatment outcomesHIV-1HIVNLXHealth qualityTherapyWeeksSuppressionGroup
2011
Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community — A potential conduit to improved HIV treatment outcomes
Saber-Tehrani AS, Springer SA, Qiu J, Herme M, Wickersham J, Altice FL. Rationale, study design and sample characteristics of a randomized controlled trial of directly administered antiretroviral therapy for HIV-infected prisoners transitioning to the community — A potential conduit to improved HIV treatment outcomes. Contemporary Clinical Trials 2011, 33: 436-444. PMID: 22101218, PMCID: PMC3268833, DOI: 10.1016/j.cct.2011.11.002.Peer-Reviewed Original ResearchConceptsHIV treatment outcomesSelf-administered therapyAntiretroviral therapyTreatment outcomesViral loadEvidence-based adherence interventionsPoor HIV treatment outcomesGenotypic resistance testingMedication-assisted treatmentDSM-IV criteriaAlcohol use disorderCase management servicesViral suppressionPrimary outcomeOpioid dependenceAdherence interventionsCD4 testingIntervention periodStudy groupEligibility criteriaUse disordersIntervention monthDrug usersAdverse HIVHIVAdherence to HIV Treatment and Care Among Previously Homeless Jail Detainees
Chen NE, Meyer JP, Avery AK, Draine J, Flanigan TP, Lincoln T, Spaulding AC, Springer SA, Altice FL. Adherence to HIV Treatment and Care Among Previously Homeless Jail Detainees. AIDS And Behavior 2011, 17: 2654-2666. PMID: 22065234, PMCID: PMC3325326, DOI: 10.1007/s10461-011-0080-2.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnalysis of VarianceAnti-HIV AgentsCross-Sectional StudiesFemaleHealth Services AccessibilityHealth Services Needs and DemandHealthcare DisparitiesHIV InfectionsHumansIll-Housed PersonsInsurance CoverageInsurance, HealthMaleMedication AdherenceMental DisordersNeeds AssessmentPrisonersSubstance Abuse, IntravenousUnited StatesVulnerable PopulationsHIV-Related Research in Correctional Populations: Now is the Time
Rich JD, Wohl DA, Beckwith CG, Spaulding AC, Lepp NE, Baillargeon J, Gardner A, Avery A, Altice FL, Springer S, On behalf of the Centers for AIDS Research—Collaboration on HIV in Corrections (CFAR-CHIC) Working Group. HIV-Related Research in Correctional Populations: Now is the Time. Current HIV/AIDS Reports 2011, 8: 288. PMID: 21904902, PMCID: PMC3208731, DOI: 10.1007/s11904-011-0095-3.Peer-Reviewed Original ResearchConceptsPrevention of HIVTransmission of HIVMental health disordersAcademic medical centerIllicit drug useEpidemic of incarcerationHIV-Related ResearchAntiretroviral therapyHIV infectionHIV transmissionMedical CenterHIVHealth disordersDrug useRisk behaviorsAIDS researchSubstance useSubstantial proportionNational InstituteRecent evidenceIncarcerated populationsPublic healthHealthCorrectional populationsPopulationPublic Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components
Springer SA, Spaulding AC, Meyer JP, Altice FL. Public Health Implications for Adequate Transitional Care for HIV-Infected Prisoners: Five Essential Components. Clinical Infectious Diseases 2011, 53: 469-479. PMID: 21844030, PMCID: PMC3156144, DOI: 10.1093/cid/cir446.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCombination antiretroviral therapyPublic health implicationsTreatment outcomesPoor HIV treatment outcomesHuman immunodeficiency virus (HIV) infectionImmunodeficiency syndrome prevalenceHIV treatment outcomesImmunodeficiency virus infectionHealth implicationsMental illness treatmentSubstance use disordersCase management servicesAntiretroviral therapySecondary preventionSyndrome prevalenceTransitional careImmunological outcomesCriminal justice populationsVirus infectionIllness treatmentUse disordersHIVMental illnessAlcohol useMedical insurance
2010
HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners
Springer SA, Azar MM, Altice FL. HIV, alcohol dependence, and the criminal justice system: a review and call for evidence-based treatment for released prisoners. The American Journal Of Drug And Alcohol Abuse 2010, 37: 12-21. PMID: 21171933, PMCID: PMC3070290, DOI: 10.3109/00952990.2010.540280.BooksMeSH KeywordsAlcoholismCriminal LawEvidence-Based MedicineHIV InfectionsHumansPrisonersUnited StatesConceptsAlcohol use disorderHIV treatment outcomesTreatment outcomesAlcohol dependencePoor HIV treatment outcomesRole of pharmacotherapyRelationship of HIVHIV risk behaviorsBetter treatment outcomesEvidence-based treatmentsAntiretroviral therapySignificant morbidityTherapeutic optionsPoor adherenceAlcohol abuseHIVUse disordersHIV cycleCommunity settingsRisk behaviorsAlcohol usePrimary articlesImproved treatmentVulnerable populationsNaltrexone